European oncology group adds Pharma Mar's Lurbinectedin to treatment guidelines

Comments Off on European oncology group adds Pharma Mar's Lurbinectedin to treatment guidelines

MADRID (Reuters) – Spain’s Pharma Mar said on Thursday that the European Society of Medical Oncology had included its Lurbinectedin drug as a treatment option for small-cell lung cancer patients in its clinical practice guidelines.

Lurbinectedin was approved by Europe’s drug regulator to treat small-cell lung cancer in 2019 and by the U.S. FDA last June.

Source: Read Full Article

Related posts:
  1. Pfizer says South African variant could significantly reduce protective antibodies
  2. Madrid residents line up for AstraZeneca shot despite blood clot link
  3. Novartis radioligand therapy improves prostate cancer survival
  4. Emergent gets $23 million additional order for vaccine production